jsonp_parse_post_list([{"post_id":"v-69f70237-124f-3ea9-acd0-fc922af945e2_c-fde81f1a-ab14-3a9b-ba4f-85206b216fd3_a-5c26370a-836f-3175-8a1b-28b899fefbf0","post_url":"https:\/\/www.yahoo.com\/newsroom\/vibes\/world-news\/market-sentiment-around-loss-making-112zxg3","author":"third_watch","provider":"Simply Wall St.","lead_attribution":"provider","link":"https:\/\/finance.yahoo.com\/news\/market-sentiment-around-loss-making-001510300.html","imgresolutions":[{"url":"https:\/\/s.yimg.com\/uu\/api\/res\/1.2\/HAI_uuypoUjC487wXkHKsw--\/YXBwaWQ9eXRhY2h5b247Zmk9c3RyaW07aD0zNjA7dz02NDA7\/http:\/\/media.zenfs.com\/en-US\/homerun\/simply_wall_st__316\/1851dac4d76e9383c0536dbafbed3a24","height":360,"width":640,"tag":"fit-width-640"},{"url":"https:\/\/s.yimg.com\/uu\/api\/res\/1.2\/21mSnkIHRIOymeTrW5eYCg--\/YXBwaWQ9eXRhY2h5b247Zmk9c3RyaW07aD0zMDA7dz0xMDgwOw--\/http:\/\/media.zenfs.com\/en-US\/homerun\/simply_wall_st__316\/1851dac4d76e9383c0536dbafbed3a24","height":300,"width":1080,"tag":"original"}],"img":"http:\/\/media.zenfs.com\/en-US\/homerun\/simply_wall_st__316\/1851dac4d76e9383c0536dbafbed3a24","imgw":1080,"imgh":300,"title":"Market Sentiment Around Loss-Making Mesoblast Limited (ASX:MSB)","summary":"Mesoblast Limited\u2019s (ASX:MSB): Mesoblast Limited develops cell-based medicines. With the latest financial year loss of -US$76.81M and a trailing-twelve month of -US$30.28M, the AU$699.91M market-cap alleviates its loss by movingRead More...","published_at":1522760598,"content_id":"5c26370a-836f-3175-8a1b-28b899fefbf0","content_url":"https:\/\/finance.yahoo.com\/news\/market-sentiment-around-loss-making-001510300.html","content_published_at":1522455310,"content_time":1522455310,"content_relative_time":95,"reaction_count":0,"vibe_name":"World News","vibe_id":"69f70237-124f-3ea9-acd0-fc922af945e2","content_type":"link","aspect":null},{"post_id":"v-69f70237-124f-3ea9-acd0-fc922af945e2_c-1e0044c7-7df1-309c-b696-a272622a5626_a-37166068-34cb-3846-a62b-a935bf76cfd3","post_url":"https:\/\/www.yahoo.com\/newsroom\/vibes\/world-news\/v-69f70237-124f-3ea9-acd0-fc922af945e2_c-1e0044c7-7df1-309c-b696-a272622a5626_a-37166068-34cb-3846-a62b-a935bf76cfd3","author":"third_watch","provider":"Motley Fool","lead_attribution":"provider","link":"https:\/\/finance.yahoo.com\/news\/apos-why-rigel-pharmaceuticals-inc-161400830.html","imgresolutions":[{"url":"https:\/\/s1.yimg.com\/uu\/api\/res\/1.2\/Zd.NNMu97gnb8GD7aAa0tw--\/YXBwaWQ9eXRhY2h5b247Zmk9c3RyaW07aD0zNjA7dz02NDA7\/http:\/\/media.zenfs.com\/en-US\/homerun\/motleyfool.com\/81414e24c8d6f861186004022308468a","height":360,"width":640,"tag":"fit-width-640"},{"url":"https:\/\/s1.yimg.com\/uu\/api\/res\/1.2\/USCyv750FirXaTsU9D4Mdw--\/YXBwaWQ9eXRhY2h5b247Zmk9c3RyaW07aD0zODc7dz01ODA7\/http:\/\/media.zenfs.com\/en-US\/homerun\/motleyfool.com\/81414e24c8d6f861186004022308468a","height":387,"width":580,"tag":"original"}],"img":"http:\/\/media.zenfs.com\/en-US\/homerun\/motleyfool.com\/81414e24c8d6f861186004022308468a","imgw":580,"imgh":387,"title":"Here's Why Rigel Pharmaceuticals Inc. Stock Is Slipping Today","summary":"Just-released trial results suggest a grim future for fostamatinib as a treatment for one rare disease.","published_at":1522759618,"content_id":"37166068-34cb-3846-a62b-a935bf76cfd3","content_url":"https:\/\/finance.yahoo.com\/news\/apos-why-rigel-pharmaceuticals-inc-161400830.html","content_published_at":1522772040,"content_time":1522772040,"content_relative_time":7,"reaction_count":0,"vibe_name":"World News","vibe_id":"69f70237-124f-3ea9-acd0-fc922af945e2","content_type":"link","aspect":null}]);